KEY TAKEAWAYS
- The phase 3 ASCEMBL trial aimed to evaluate the healthcare resource utilization (HCRU) rates compared to bosutinib in 3L+ chronic myeloid leukemia (CML-CP) patients.
- Patients were randomized to receive asciminib 40 mg twice daily (n = 157) or bosutinib 500 mg once daily (n = 76).
- Rates of HCRU per patient-year were significantly lower for asciminib than bosutinib at Week 24, Week 48, and Week 96 analyses.
- Asciminib showed shorter hospital stays compared to bosutinib across various wards in the long-term ASCEMBL trial.
In the randomized ASCEMBL trial, the objective was to evaluate and compare the health care resource utilization (HCRU) between asciminib and bosutinib in 3L+ patients with chronic phase chronic myeloid leukemia (CML-CP) at Week 24, Week 48, and Week 96 endpoints. A total of 233 patients were enrolled in the trial (asciminib: n = 157, bosutinib: n = 76), as per Clinicaltrials.gov identifier NCT03106779. During scheduled visits, healthcare resource utilization, including hospitalizations, emergency room visits, general practitioner visits, specialist visits, and urgent care visits, were assessed by investigators. For hospitalized patients, the duration and type of hospitalization and the reasons for healthcare resource utilization were recorded. The analysis involved comparing the number of patients with healthcare resource utilization, the rate of healthcare resource utilization per patient-year, and the length of hospital stay by ward type across the Week 24, Week 48, and Week 96 time points.
Asciminib-treated patients exhibited lower healthcare resource utilization (HCRU) proportions, including hospitalizations, ER visits, GP visits, specialist visits, and urgent care visits (Week 24: 23.6% vs. 36.8%, Week 48: 26.1% vs. 39.5%, Week 96: 28.6% vs. 42.6%). After normalizing treatment exposure, asciminib showed significantly lower HCRU rates per patient-year compared to bosutinib: Week 24: 0.25 (95% CI: 0.18-0.34) vs. 0.80 (95% CI: 0.55-1.16), Week 48: 0.20 (95% CI: 0.15-0.27) vs. 0.47 (95% CI: 0.32-0.66), Week 96: 0.17 (95% CI: 0.12-0.22) vs. 0.40 (95% CI: 0.27-0.55). Asciminib also demonstrated shorter hospital stays for most wards among hospitalized patients throughout the study.
The results revealed that Asciminib-treated patients with chronic myeloid leukemia in the chronic phase (CML-CP) who were in the third-line or beyond showed sustained lower resource utilization compared to bosutinib in the long term.
Source:https://pubmed.ncbi.nlm.nih.gov/37431294/
Clinical Trial: https://classic.clinicaltrials.gov/ct2/show/NCT03106779
Cortes JE, Rea D, Mauro MJ, Tran D, Wang P, Jadhav K, Yocolly A, Sasaki K. Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib. J Med Econ. 2023 Jul 11:1-26. doi: 10.1080/13696998.2023.2234776. Epub ahead of print. PMID: 37431294.
